How is the PREVENT 10‑year cardiovascular disease risk score calculated?

PREVENT Score Calculation

The PREVENT (Predicting Risk of Cardiovascular Disease Events) score is calculated using age, sex, systolic blood pressure, antihypertensive medication use, total cholesterol, HDL cholesterol, diabetes status, smoking status, estimated glomerular filtration rate (eGFR), and urine albumin-to-creatinine ratio (uACR) to estimate 10-year risk of atherosclerotic cardiovascular disease (ASCVD) events. 1, 2, 3

Core Variables Required

The PREVENT equations come in two versions—Base and Full—both requiring the following core parameters 2, 3:

• Age (40–75 years for primary prevention)
• Sex (male or female)
• Systolic blood pressure (mmHg)
• Antihypertensive medication use (yes/no)
• Total cholesterol (mg/dL)
• HDL cholesterol (mg/dL)
• Diabetes status (yes/no)
• Current smoking status (yes/no)
• Estimated glomerular filtration rate (eGFR) (mL/min/1.73 m²)

Additional Variables for PREVENT Full

The PREVENT Full equation incorporates three additional variables to refine risk estimation 2, 4:

• Urine albumin-to-creatinine ratio (uACR) (mg/g)
• Hemoglobin A1c (HbA1c) (%)
• Social Deprivation Index (SDI) (a composite measure of neighborhood socioeconomic disadvantage)

Key Differences from Pooled Cohort Equations

PREVENT removes race as a variable and adds kidney function markers (eGFR and uACR), making it more accurate for contemporary populations 2, 3, 4. The PREVENT equations estimate 10-year risk of total ASCVD events (myocardial infarction, fatal coronary heart disease, and fatal/nonfatal ischemic stroke), similar to the Pooled Cohort Equations (PCE), but with superior calibration 2, 3, 4.

Performance Characteristics

PREVENT demonstrates better calibration than the PCE, which consistently overestimates risk in modern populations 2, 3, 4. In validation studies:

• Discrimination: PREVENT achieves a C-statistic of 0.741–0.743, comparable to PCE (0.741), but with improved performance in men, non-Hispanic Black adults, and those with chronic kidney disease 2, 4, 5
• Calibration: PREVENT shows mean calibration ratios of 0.85–1.36 (near-perfect), while PCE overestimates risk with ratios of 1.80–2.18 2
• Age-specific performance: PREVENT performs best in adults aged 30–54 years and maintains good discrimination even in those ≥80 years (C-statistic 0.854) 5, 6

Clinical Impact on Treatment Decisions

Using PREVENT instead of PCE would reclassify approximately 42–45% of patients to lower risk categories, potentially reducing the number of adults eligible for primary prevention statin therapy from 45.4 million to 28.3 million in the United States 3, 4. This represents 17.3 million fewer adults recommended for statins, including 4.1 million currently taking statins 3.

Calculation Access

The PREVENT calculator is available online through the American Heart Association at tools.acc.org or through the AHA PREVENT calculator website 1, 3. The calculator automatically computes 10-year ASCVD risk based on entered variables and can be used with either the Base equation (if uACR, HbA1c, or SDI are unavailable) or the Full equation when all variables are available 2, 4.

Special Population Considerations

PREVENT performs particularly well in specific subgroups 4, 5, 7:

• Women: More accurate than PCE (3.3% discordance vs. observed events) 4
• Non-smokers: Better calibration (2.4% discordance) compared to smokers 4
• Chronic kidney disease stages 3/4: Improved accuracy (3.2% discordance) 4
• High social deprivation: Better risk stratification (-5.0% discordance) 4
• Older adults ≥80 years: Superior discrimination (C-statistic 0.854) compared to PCE (0.799) 5

Important caveat: PREVENT significantly underestimates risk in people with HIV, with observed risks more than double predicted risks (observed-to-expected ratio 2.69), requiring HIV-specific risk adjustment 7.